A new FDA rule that would govern off-label marketing has drugmakers in a minor tizzy—and they're demanding that the agency set its change aside.

With a collective head smack last week, pharma industry digital insiders read about WebMD’s decision to pursue a sale or merger after some reports blamed the…

Masking depression is never a good idea. Otsuka and Lundbeck are back on the air to make that case with a new TV ad for antipsychotic Rexulti.

The market for hepatitis C drugs is shrinking. Shortly after spending $3.9 billion on Idenix, Merck is taking a $2.9 billion hit on an experimental compound.

Remember when Valeant was counting on a sales force beef-up to revive its struggling GI franchise? It may have just run into a big problem in that department.…

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…

If all baby boomers got tested for hep C, that could help stem freefall of Gilead's blockbusters—and it's exactly the move the company is…

Activist investors have moved in on Bristol-Myers Squibb, including Carl Icahn, who has a long history of pushing drugmakers to put themselves on the block.

Marketing